Can Celltrion's Remicade biosim kneecap J&J's in the U.S.?

The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's ($PFE) Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson ($JNJ) that it's been stealing in Europe from Merck & Co. ($MRK)? Depends who you ask. More from FiercePharma

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.